Department of Cardiology, Zhongshan Hospital, Fudan University, 1609 Xietu Road, Shanghai 200032, P. R. China.
Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, P. R. China.
Eur Heart J Qual Care Clin Outcomes. 2022 Nov 17;8(8):871-880. doi: 10.1093/ehjqcco/qcab103.
This study aimed to investigate the prognostic implications of increased post-procedural cardiac troponin levels in patients undergoing elective percutaneous coronary intervention (PCI) and to define the threshold of prognostically relevant periprocedural myocardial injury (PMI).
A total of 3249 patients with normal baseline troponin levels referred for elective PCI were enrolled and followed up for a median period of 20 months. The primary endpoint was major adverse cardiovascular events (MACEs) comprising all-cause death, myocardial injury (MI), and ischaemic stroke. Post-PCI high-sensitivity cardiac troponin T (hs-cTnT) >99% upper reference limit (URL) occurred in 78.3% of the patients and did not increase the risk of MACEs [adjusted hazard ratio (adHR) 1.00, 95% confidence interval (CI) 0.58-1.74, P = 0.990], nor did 'major PMI', defined as post-PCI hs-cTnT >5× URL (adHR 1.30, 95% CI 0.76-2.23, P = 0.340). Post-PCI troponin >8× URL, with an incidence of 15.2%, started to show an association with a higher risk of MACEs (adHR 1.89, 95% CI 1.06-3.37, P = 0.032), mainly driven by myocardial infarction (adHR 2.38, 95% CI 1.05-5.38, P = 0.037) and ischaemic stroke (adHR 3.35, 95% CI 1.17-9.64, P = 0.025).
In patients with normal baseline troponin values undergoing elective PCI, PMI defined as hs-cTnT >8× URL after PCI was more appropriate for identifying patients with an increased risk of MACEs, which may help guide clinical practice in this population.
本研究旨在探讨择期经皮冠状动脉介入治疗(PCI)术后心脏肌钙蛋白水平升高的预后意义,并确定与围术期心肌损伤(PMI)相关的预后界值。
共纳入 3249 例基线肌钙蛋白正常的择期 PCI 患者,中位随访时间为 20 个月。主要终点为全因死亡、心肌损伤(MI)和缺血性卒中组成的主要不良心血管事件(MACE)。78.3%的患者术后高敏心肌肌钙蛋白 T(hs-cTnT)>99%的上限(URL),但不增加 MACE 风险[校正后的危险比(adHR)为 1.00,95%置信区间(CI)为 0.58-1.74,P=0.990],“主要 PMI”(定义为 PCI 后 hs-cTnT>5×URL)也不增加 MACE 风险(adHR 为 1.30,95%CI 为 0.76-2.23,P=0.340)。hs-cTnT>8×URL 的发生率为 15.2%,开始显示与更高的 MACE 风险相关(adHR 为 1.89,95%CI 为 1.06-3.37,P=0.032),主要与心肌梗死(adHR 为 2.38,95%CI 为 1.05-5.38,P=0.037)和缺血性卒中(adHR 为 3.35,95%CI 为 1.17-9.64,P=0.025)相关。
在基线肌钙蛋白正常的择期 PCI 患者中,PCI 后 hs-cTnT>8×URL 定义的 PMI 更适合识别 MACE 风险增加的患者,这可能有助于指导该人群的临床实践。